



Cancer Research

AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH



March 15, 1996
Volume 56 • Number 6
PP. 1179-1469
ISSN 0008-5472 • CNREA 8



International Aspirin® Award 1996

Young Researchers' Aspirin® Award

The Young Researchers' Aspirin® Award's objective is to encourage scientific research into the mechanism of action and clinical use of acetylsalicylic acid, the active ingredient of Aspirin®. Scientists who have contributed to the knowledge of Aspirin® through original independent scientific research in the field of theoretical (experimental) and/or clinical medicine are invited to compete for the Award. The results of their work should have a direct effect on the knowledge or use of Aspirin® and be based on a peer-reviewed publication, accepted and/or published. The publication should not be older than two years. The age limit of the Young Researchers' Aspirin® Award in the year of candidature is 40.

The Young Researchers' Aspirin® Award's value is DM 20,000.

Entries will be judged by an international scientific committee representing basic and clinical research.

Submit your manuscript (English language, 2 copies) with your Curriculum Vitae, a list of the 5 most important recent publications (= last 5 years) and a statement of your Head of Department confirming the independence of the scientific work and indicating the sources of financial funding.

Applications should be mailed to the following address:

International Aspirin® Award
c/o Bayer AG
BG Consumer Care/MC
Building C 151
D-51368 Leverkusen/Germany

Deadline for postal mark of submission is April 30th, 1996.



The Pezcoller Foundation, Trento, Italy

The Pezcoller Foundation is a non-profit organization created in 1979 by Prof. Alessio Pezcoller, who was the chief Surgeon of the S. Chiara Hospital of Trento, Italy. One of the goals of the Foundation is to promote biomedical research. To this end, among its activities, it annually sponsors a symposium at the cutting edge of basic research. These symposia are structured to favor intensive discussions among participants leading to the development of new ideas and perspectives and new scientific cooperative endeavors. The topics are chosen by an International Advisory Committee composed of: E. Mihich, Chairman (Buffalo), D. Livingston, Vice-Chairman (Boston), G. Bernardi (Trento), B. Chabner (Boston), R. Dalla Favera (New York), G. Della Porta (Milan), T. Graf (Germany), P. Schlechter (Trento), T. Taniguchi (Tokyo), F. Zuelli (Trento).

Eighth Pezcoller Symposium, June 17-19, 1996, Trento, Italy **Genomic Instability and Immortality in Cancer**

Co-Chairs: E. Mihich, L. Hartwell and C. Greider

Program Committee: Drs. E. Mihich (Chairman), C. Greider, L. Hartwell
G. Anderson, M. Bignami and D. Livingston

June 17, AM, Session I: Mutational Lability, Co-Chairs: William Burhans and George Stark

Maurizio Gatti Telomeres and cell division in *Drosophila*
Joe Gray Genomic instability and solid tumor progression: a molecular cytogenetic view
Geoffrey Wahl Cell cycle control of genetic stability

June 17, PM, Session II: Recombination and Repair, Co-Chairs: Margherita Bignami and Dirk Bootsma

Richard Kolodner Mismatch repair and cancer susceptibility
Miroslav Radman The role of sequence polymorphism, mismatch repair and apoptosis in genomic stability and cancer avoidance
Jan Hoeijmakers Recombining DNA damage repair, basal transcription and human syndromes

June 18, AM, Session III: Telomerase and immortalization, Co-Chairs: Silvia Bacchetti and Jerry Shay

Vincent Schulz *De novo* telomere formation in yeast
Michael McEachern Consequences of altered telomeres in yeast
Howard Cooke Recombination in mammalian telomeres

June 18, PM, Session IV: Cell Cycle Checkpoint and Apoptosis, Co-Chairs: René Bernards and Jean-Marc Egly

Leland Hartwell Genomic instability, cell cycle control and cancer
Kim Nasmyth Proteolysis and the cell cycle
Gerard Evan The integrated control of cell proliferation and cell viability

June 19, AM, Session V: Clinical Potentialities and Integration, Co-Chairs: Wilhelm Krek and Carlo Croce

Brian Reid Barrett's esophagus: The cell cycle and genomic instability in neoplastic progression
David Livingston The RB gene product and its targets
Giulio Draetta Anomalies of cell cycle controls in human cancer
Richard Klausner Synopsis and projections

For further information on the Eighth Symposium, please contact Dr. E. Mihich, Roswell Park Cancer Institute, Buffalo, NY 14263, USA, Tel: 716-845-8225; Fax: 716-845-8857; Email: toscani@sc3103.med.buffalo.edu. For local arrangements, Mr. Giorgio Pederzoli, The Pezcoller Foundation, 38100 Trento, Italy, Tel: 39-461-980 250; Fax: 39-461-980 350.

AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Inducible Genomic Responses



June 8-12, 1996
Skamania Lodge
Stevenson (Columbia River Gorge), WA

CONFERENCE CO-CHAIRPERSONS

William T. Beck / Memphis, TN **John A. Hickman** / Manchester, England
Richard I. Morimoto / Evanston, IL

CONFERENCE PROGRAM

Effects of UV and Oxidative Stress on Signal Transduction and Gene Regulation in Eukaryotes

Tom Curran / Memphis, TN
Michael Karin / La Jolla, CA
Rex M. Tyrrell / Lausanne, Switzerland

Oxidative Stress and DNA Damage in Prokaryotes

Gisela T. Storz / Bethesda, MD
Graham C. Walker / Cambridge, MA

Heat Shock Responses and Molecular Chaperones

Richard I. Morimoto / Evanston, IL
Costa P. Georgopoulos / Geneva, Switzerland
Linda M. Hendershot / Memphis, TN

Mechanisms of Detection and Response to Heavy Metals and Drugs

Thomas V. O'Halloran / Evanston, IL
Frank J. Gonzalez / Bethesda, MD
John A. McLachlan / New Orleans, LA

Cytotoxic Signaling Pathways and Apoptosis

Douglas R. Green / La Jolla, CA
John A. Hickman / Manchester, England
John C. Reed / La Jolla, CA

Monitoring Genomic Integrity After Cytotoxic Insult: DNA Topology, Protein Kinases, and DNA Repair

Merl F. Hoekstra / Bothell, WA
Stephen P. Jackson / Cambridge, England
Ian D. Hickson / Oxford, England

Monitoring Genomic Integrity After Cytotoxic Insult: DNA Damage, p53, and Repair

Albert J. Fornace, Jr. / Bethesda, MD
James M. Ford / Stanford, CA
Jo Milner / York, England

Attenuation of Cytotoxic Signals, Genetic Suppressor Elements, and DNA Repair as Mechanisms of Drug Resistance

Tomas Lindahl / South Mimms, England
Andrei V. Gudkov / Chicago, IL
Kimitoshi Kohno / Fukuoka, Japan
William T. Beck / Memphis, TN

Protein Degradation

Wolfgang Baumeister / Martinsried, Germany
Martin Rechsteiner / Salt Lake City, UT
Aaron Ciechanover / Haifa, Israel

Plenary Session

David P. Lane / Dundee, Scotland

Application Deadline: April 1, 1996

Information and Application Forms:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
E-mail: aacr@aol.com

CLINICAL TRIALS PROGRAM

PROSTATE CANCER INITIATIVE OF THE CANCER RESEARCH INSTITUTE

The Cancer Research Institute announces the availability of Clinical Research Seed Grants to support Phase I or Phase I/II trials. The Institute is planning to make individual grants in the amount of \$150,000 over two years to support clinical research aimed at testing novel therapies for advanced prostate cancer with particular emphasis on hormonal therapy and immunotherapy. The Cancer Research Institute does not provide funds for indirect costs. The deadline for receiving applications (including the clinical protocol) is May 15, 1996. The clinical research may be conducted in the United States or abroad, at nonprofit medical centers or hospitals.

For applications, please contact:

Ms. Lynne Harmer
Director of Grants Administration
Cancer Research Institute
681 Fifth Avenue
New York, NY 10022-4209
212-688-7515 or FAX 212-832-9376



Research Pharmacologist

Southern Research Institute is an independent, contract research organization serving government, industry, academia and individuals. A position is available for a scientist with a Ph.D. in Pharmacology or related discipline to join a team of researchers conducting *in vivo* and *in vitro* studies in cancer chemoprevention, chemotherapy, drug evaluation, and experimental model development. This research program has a 35-year record of productive anti-cancer drug development through interactions with other scientists, private sponsors, and grant-funded research.

To apply, send c.v. to Suzann Allen, Human Resources Dept. 104, Southern Research Institute, P.O. Box 55305, Birmingham, AL 35255-5305.

We are an equal opportunity/affirmative action employer.

AMERICAN CANCER SOCIETY
Atlanta, Georgia

SCIENTIFIC PROGRAM DIRECTOR

The American Cancer Society is seeking applicants for the position of Scientific Program Director in the Research Grants Department at the National Home Office in Atlanta, Georgia. The start date is August 1, 1996.

The overall responsibility of this position is to ensure unbiased, rigorous peer review of grant applications by the Society's Scientific Advisory Committees. The successful candidate will be responsible for managing the peer review of applications for clinical research and training awards. In addition, Scientific Program Directors serve as expert sources of information on advances in cancer research, advise about promising future areas of investigation in their specific areas of expertise, and participate in collaborative projects throughout the Society.

Applicants must have an MD or equivalent degree plus five years of recent experience as an established investigator on peer reviewed clinical or related oncology research projects. The position is largely administrative and reports to the Vice President for Research Grants. Salary is commensurate with the candidate's qualifications and experience.

The American Cancer Society's National Research Program (Extramural Grants, Intramural Epidemiology and Surveillance Research, and the Behavioral Research Unit) is housed in the National Home Office, in close proximity to Emory University and the Centers for Disease Control and Prevention. For confidential consideration, please send letter of interest, curriculum vitae and the names of three references by May 1, 1996 to: **John J. Stevens, MD, Vice President for Research Grants, American Cancer Society, 1599 Clifton Rd, N.E., Atlanta, GA 30329-4251**



EQUAL OPPORTUNITY EMPLOYER, M/F/D/V

